Liraglutide is more successful in reducing glycated hemoglobin levels to 7% or less regardless of baseline glycated hemoglobin level compared with sitagliptin in adults with type 2 diabetes, said Melanie Davies, MD, MB ChB, professor of diabetes medicine, University of Leicester, United Kingdom.
Liraglutide is more successful in reducing glycated hemoglobin levels to 7% or less regardless of baseline glycated hemoglobin level compared with sitagliptin in adults with type 2 diabetes, said Melanie Davies, MD, MB ChB, professor of diabetes medicine, University of Leicester, United Kingdom.
Davies presented a post hoc analysis of a 26-week, randomized, open-label trial comparing the 2 agents in which she examined the effect of baseline glycated hemoglobin on the level of glycemic control achieved. In the study, 437 patients with type 2 diabetes treated with metformin for at least 3 months and baseline glycated hemoglobin levels of 7.5% to 10.0% were assigned to liraglutide 1.8 mg/day or sitagliptin 100 mg/day. As presented previously, mean A1c levels were reduced by a mean of 1.5% with liraglutide compared with 0.9% with sitagliptin (P1c less than 7% (55% vs 22%, respectively; P)
In the current analysis, patient groups were split into 5 categories according to their baseline glycated hemoglobin levels (≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and >9.0%). The findings across these categories were
At each baseline category of glycated hemoglobin , significantly more liraglutide recipients than sitagliptin recipients achieved an glycated hemoglobin level less than 7%. In the liraglutide group, 85% of those with baseline glycated hemoglobin less than 7.5% achieved their target of 7% or less, and more than 30% in the highest 2 baseline groups achieved their target glycated hemoglobin . By comparison, only 36% of patients with baseline glycated hemoglobin levels less than 7.5% achieved their target with sitagliptin, and less than 20% of those with baseline glycated hemoglobin >8.5% achieved their glycemic target with sitagliptin.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More